Mao et al. (2010) showed that depletion of BLM by RNAi-mediated shRNA gene silencing suppresses the growth of osteosarcoma U2OS cell line with an increase in DNA damage detected by gamma-H2AX, suggesting that BLM is a potential target for anticancer therapeutics. The gene discussed is BLM; the disease is osteosarcoma.